Fig. 5: Anti-Mstn treatment effectively reduces bone lesions and OC formation in a syngeneic 4T1 mouse model of BC metastases. | Oncogene

Fig. 5: Anti-Mstn treatment effectively reduces bone lesions and OC formation in a syngeneic 4T1 mouse model of BC metastases.

From: Pharmacological inhibition of myostatin effectively ameliorates osteolytic lesions in syngeneic and xenograft breast cancer mouse models

Fig. 5: Anti-Mstn treatment effectively reduces bone lesions and OC formation in a syngeneic 4T1 mouse model of BC metastases.

A Effects of anti-Mstn antibody treatment on trabecular and cortical bone parameters. Shown are representative images of a defined area of μCT-reconstructed tibiae. The tibiae of naïve (healthy control) (n = 8), anti-Mstn-treated (n = 7) and vehicle mice (n = 9) were analyzed for trabecular bone volume fraction (BV/TV, %), trabecular thickness (Tb. Th, mm), trabecular number (Tb.N, 1/mm) and trabecular separation (Tb.Sp., mm) as well as cortical bone fraction (Cort. BV/TV, %) and cortical thickness (Cort. Th, mm) using the BRUKER μCT CTAn software. Left and right tibiae were analyzed. B TRAP-positive OCs in tibiae sections of naïve (healthy control) (n = 3), vehicle (n = 4) and anti-Mstn-treated mice (n = 4). Shown are individual values and mean ± SEM, one-way ANOVA, Kruskal-Wallis test with multiple comparisons, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. Scale bar 200 μm.

Back to article page